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Abstract
Tumour cells communicate with the cells of their microenvironment via a series of molecular and cellular interactions
to aid their progression to a malignant state and ultimately their metastatic spread. Of the cells in the
microenvironment with a key role in cancer development, tumour associated macrophages (TAMs) are among the
most notable. Tumour cells release a range of chemokines, cytokines and growth factors to attract macrophages, and
these in turn release numerous factors (e.g. VEGF, MMP-9 and EGF) that are implicated in invasion-promoting
processes such as tumour cell growth, flicking of the angiogenic switch and immunosuppression. TAM density has
been shown to correlate with poor prognosis in breast cancer, suggesting that these cells may represent a potential
therapeutic target. However, there are currently no agents that specifically target TAM’s available for clinical use.
Bisphosphonates (BPs), such as zoledronic acid, are anti-resorptive agents approved for treatment of skeletal
complication associated with metastatic breast cancer and prostate cancer. These agents act on osteoclasts, key
cells in the bone microenvironment, to inhibit bone resorption. Over the past 30 years this has led to a great
reduction in skeletal-related events (SRE’s) in patients with advanced cancer and improved the morbidity
associated with cancer-induced bone disease. However, there is now a growing body of evidence, both from in
vitro and in vivo models, showing that zoledronic acid can also target tumour cells to increase apoptotic cell death
and decrease proliferation, migration and invasion, and that this effect is significantly enhanced in combination
with chemotherapy agents. Whether macrophages in the peripheral tumour microenvironment are exposed to
sufficient levels of bisphosphonate to be affected is currently unknown. Macrophages belong to the same cell
lineage as osteoclasts, the major target of BPs, and are highly phagocytic cells shown to be sensitive to
bisphosphonates in model studies; In vitro, zoledronic acid causes increased apoptotic cell death; in vivo the drug
has been shown to inhibit the production of pro-angiogenic factor MMP-9, as well as most recent evidence
showing it can trigger the reversal of the TAMs phenotype from pro-tumoral M2 to tumoricidal M1. There is thus
accumulating evidence supporting the hypothesis that effects on TAMs may contribute to the anti-tumour effect
of bisphosphonates. This review will focus in detail on the role of tumour associated macrophages in breast cancer
progression, the actions of bisphosphonates on macrophages in vitro and in tumour models in vivo and summarise
the evidence supporting the potential for the targeting of tumour macrophages with bisphosphonates.
Keywords: Bisphosphonates, macrophages, zoledronic acid, tumour microenvironment, tumour-associated macro-
phages, anti-tumour effect, mevalonate pathway
Introduction
Breast cancer is the most commonly diagnosed cancer
in the UK where women have a 1 in 8 lifetime risk of
developing the disease [1]. The majority of breast cancer
patients will present with a localised tumour, however at
least 5% of patients will present with advanced meta-
static disease, and it is estimated that a further 30% will
go on to develop this within 10 years. The most com-
mon site of metastatic spread is bone, occurring in
approximately 80% of advance disease patients. The
consequences of bone metastases include bone pain,
pathological fractures and hypercalcaemia, - collectively
known as skeletal-related-events (SREs) have decreased
over the past 30 years; this is mainly to the introduction
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cancer treatment. This widespread use has lead to
increasing interest in the potential for the bisphospho-
nates to affect tumour growth, both as a consequence of
reduced bone resorption but also through actions on
tumour cells and cells of the tumour microenvironment,
including macrophages [2].
Macrophages in the tumour microenvironment
Cancer cells work in conjunction with cells in the sur-
rounding microenvironment to aid numerous processes
needed for tumour development. Macrophages are a
major component of this microenvironment, and are of
particular interest as potential therapeutic targets due to
their central role in tumour progression.
Macrophages are lymphocytes of the myeloid lineage,
derived from CD34+ bone marrow progenitor cells (see
Figure 1) [3,4]. Pro-monocytes develop into monocytes
in the bloodstream and can then either circulate as
inflammatory monocytes, that differentiate into macro-
phages in inflamed tissue, or extravasate into tissues and
differentiate into resident macrophages [3,4]. Resident
macrophages have different phenotypes depending on
t h et i s s u et h e yr e s i d ei n ,f o re x a m p l e :K u p f f e rc e l l si n
the liver, microglia in the brain and Langerhan cells in
the skin. Both types of macrophages, inflammatory and
resident, are phagocytes, and both perform a range of
essential biological functions [3-6].
Macrophages possess phenotypic plasticity that can be
classified into two types, M1 (Type I) and M2 (Type II)
polarised macrophages. These have different characteris-
tics and functions within the body and immune system;
shown by the varying types and amounts of cytokines
they produce (see Table 1) [3-6].
M1 macrophages, also known as classically activated
macrophages, play various roles in both arms of the
immune system. In the innate immune system they
guard against infection by engulfing and digesting invad-
ing microbes, as well as defending against tumour cells
by releasing cytotoxic nitric oxide and reactive oxygen
intermediates. In the adaptive immune system they
operate as lymphocyte activators by presenting antigens
to polarised type I T cells and secreting immunomodu-
latory and proinflammatory cytokines [3-6].
M2 macrophages (also known as alternatively acti-
vated macrophages) are better adapted to scavenging
debris, and secrete growth factors that promote angio-
genesis. They show reduced immune activity such as
poor antigen-presenting capabilities and suppress T cell
and natural killer cell proliferation and activity. They are
Figure 1 Development of different types of macrophages from multipotent hematopoetic stem cells.
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injury by engulfing cell debris, regulating tissue remo-
delling and repair and control normal cell turnover
[3,6]. M2 macrophage classification can be broken down
further into M2a, M2b and M2c classes depending on
environmental signals that induce their activation, with
M 2 cb e i n gt h em o r ei m m u n o s u p p r e s s i v eo ft h e s ep h e -
notypes [7,8]. However it must be noted that there is a
degree of overlap between the different types of macro-
phages and separation of them is neither easy nor clear-
cut.
Tumour associated Macrophages (TAMs)
The tumour stroma plays a central role in tumour pro-
gression. Via cellular and molecular interactions
between the stroma and the tumour cells, the stoma is
able to change with the tumour as it evolves [9]. Cells
of the tumour stroma include macrophages, fibroblasts,
lymphocytes, other bone marrow derived cells, pericytes,
myeloid-cell derived suppressor cells, mesenchymal stem
cells and blood and lymphatic vessels [5].
Primary and secondary tumours are associated with
chronic inflammation leading to recruitment of bone
marrow derived cells, macrophages are a major compo-
nent of this inflammatory infiltrate and thus of the
tumour stroma itself [5,10]. Tumours are capable of
altering the function of many biological systems, the
prime example being the “hijacking” of this inflamma-
tory infiltrate to aid tumour progression. Pre-invasive
tumour cells release chemotactic factors that attract cir-
culating monocytes into the tumour stroma. In breast
cancer these factors include, colony stimulating factors
(CSF-1) [11], vascular endothelial growth factor (VEGF)
[12] and many CC chemokines such as CCL2, CCL3,
CCL4, CCL5 and CCL8, monocyte chemotactic protein
- 1 (MCP-1) [6,13,14], see Table 1 for details.
Once in the tumour stroma the macrophages differ-
entiate into tumour-associated macrophages (TAMs). It
has been proposed that exposure to the tumour cells
and to additional tumour-derived molecules such as IL-
4, IL-10, IL-13, TGFb-1 (transforming growth factor -
b) and PGE2 (Prostaglandin E2) initiates the develop-
ment of TAMs, as well as initiating the development of
characteristics akin to those of the M2 macrophages
[3,6]. The “M2 polarised macrophage characteristics”
TAMs develop are advantageous to the tumour as they
support growth, invasion, migration and metastatic
spread. TAMs also produce a wide range of pro-angio-
genic and immunosuppressive factors. In other words,
macrophages are recruited into the tumour microenvir-
onment and then “educated” to regulate inflammation
and support the progression of the tumour [5]. These
activities will be discussed in more detail below.
It is generally accepted that TAMs have mostly pro-
tumoral functions [5] and play an important role in sev-
eral stages of tumour progression. This progression
involves a series of events that leads from the primary
site to the metastatic site, including tumour cell growth,
angiogenesis, migration, invasion, intravasation and
finally extravasation at distant site where the process
begins again (metastasis). Simultaneous immunosup-
pression is also needed to facilitate this process, as this
allows cancer cells to evade detection by immune cells
and therefore travel unharmed in the circulation where
they adhere and extravasate at distant sites. Macro-
phages act like the “Jack-of-all-trades”, being involved in
all of these processes described in the following sections
(Figure 2) [15,16].
Table 1 Difference between M1, M2 and TAM activation, membrane receptors, cytokines/chemokines produced and
markers
M1-Classically
Activated
M2-Alternatively
Activated
TAMS References
Activation INFg, LPS IL-4, IL-13, IL-10 CSF-1, VEGF, CCL2, CCL3, CCL4, CCL5, CCL8, MCP-1, IL-4, IL-13,
IL-10, TGFb-1, PGE2.
Coffelt et al
[4]
Joyce and
Pollard [9]
Mantovani
et al [84]
Membrane
Receptors
TLR2, TLR4, CD16,CD32,
CD64, CD80, CD86
Scavenger receptor A,
Scavenger receptor B,
CD14, CD23, CD163
CD11b
+, CD14
-, CD31
-, CD45
+, CD68
+, CD117
-, CD122
-, CD146
-,
CD204
+, CD206
+, CCR2
+,CSF1R
+, MHCII
+, CD23
+, CD163
+,
CXCR4
+, VEGFR1
+, VEGFR2
-, F4/80
+(mice)
[4,9,84]
Cytokines
produced
IL-1, IL-6, IL-12, TNF, RNI,
ROI
IL-1ra, IL-1 decoy receptor,
EGF, FGF, VEGF, TNF-b,
bFGF, FGF, HFG, EGFR, PDGF, VEGF, ANG1, ANG2, IL-1, IL-8,
TNF-a, TP, MMP-2, MMP-2, MMP-9, NO, CSF-1
[4,9,84]
Chemokines
produced
CCL-2, CCL-3, CCL-4,
CCL-5 CXCL8, CXCL9,
CXCL10, CXCL11
CCL-12, CCL-16, CCL-17,
CCL-18, CCL-22, CCL-24
CCL-2, CCL-3 [4,9,84]
Marker iNOS Arginase F4/80 (mice), CD34 (humans) [4,9,84]
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Angiogenesis is a key step in tumour progression, with-
out which, tumours would not be able to survive and
progress. Only tumours with a maximum of 2 mm dia-
meter can be perfused by simple diffusion and anything
larger than this needs an additional blood supply [17].
The change in tumour phenotype from angiostatic to
angiogenic is known as the angiogenic switch, and is a
prerequisite for the progression of the tumour to a
malignant state and for its metastatic spread [10,17].
Angiogenesis is an intricate process involving synchro-
nised basement membrane degradation and endothelial
cell proliferation and migration [18]. There is a wealth
of research linking tumour-associated macrophages to
increased angiogenesis, with many published reports
focussing on the molecular mechanisms of this process
[6,12,17,19-21].
TAMs gather in avascular tumour “hotspots”,a r e a so f
necrosis with few blood vessels, and there is an inverse
relationship between macrophage density and vascular
density [19]. Angiogenesis is triggered by tumour hypoxia;
where an area of tissue is deprived of an adequate oxygen
supply. The low oxygen tension up-regulates the expres-
sion of certain chemoattractants including VEGF and
endothelins EL-1 and EL-2, which attracts TAMs into
hypoxic tumour sites where they are then immobilised by
down-regulating chemoattractant receptors [6,22].
Hypoxia also causes increased expression of factors encod-
ing for pro-angiogenic genes, e.g. hypoxia-inducible tran-
scription factors HIF-1 and HIF-2 [23]. These up-regulate
TAM production of pro-angiogenic growth factors and
cytokines such as matrix metalloproteinase-9 (MMP-9),
vascular-endothelial growth factor (VEGF), platelet-
derived growth factor (PDGF), fibroblast growth factor 2
(FGF2), tumour necrosis factor-a (TNF-a), COX-2,
MMP-7, MMP-12 [6]. TAMs and tumour cells work
together in a series of paracrine loops. For example,
TAMs produce of IL-1 which induces HIF-1 expression
by the tumour and this is known to up-regulate the pro-
duction of VEGF by TAMs [17]. TAMs also work in auto-
crine loops, and TAMs in poorly vascularised breast
cancers are shown not only to express VEGF but also to
respond to it [12]. VEGF is a pro-angiogenic factor that
stimulates the proliferation and migration of endothelial
cells needed for capillary formation. Inhibiting VEGF-A
expression with bevacizumab, (a fully human anti-VEGF
antibody) in SCID mice with established orthotopic MDA-
MB-231 breast tumours caused reduced TAM infiltration
which was correlated with reduced microvessel density
and reduced VEGF-induced angiogenesis [20]. TAMs also
produce matrix-metalloproteinases such as MMP-7 and
MMP-9. MMP-9 is a stromal factor essential for angiogen-
esis; it remodels the extracellular matrix and promotes the
sprouting and growth of new blood vessels by making
Figure 2 Role of tumour associated macrophages in tumour progression.
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cells [21]. MMP-7 promotes endothelial cell proliferation
and migration thus supporting angiogenesis [6].
A study using CSF-1 null mutant PyMT mice showed
that macrophage infiltration was a prerequisite for the
angiogenic switch which correlates with the transition of
the tumour phenotype to malignancy [11]. This is sup-
ported by other studies in different cancers including:
oral squamous cell carcinoma, where it was found that
increased TAM infiltration was associated with higher
histopathological grade [24], as well as in malignant
melanoma [25], where a positive correlation between
mean macrophage count and mean vascular count was
found [11,24,25].
The role of TAMs in tumour growth
TAMs are evidently multifunctional and can influence
tumour growth both indirectly and directly [6]. The for-
mer, as described above, is mediated through their role
in angiogenesis, which is essential for tumour growth as
it provides oxygen and nutrients [18]. However they are
also more directly involved; TAMs secrete a number of
mitogenic cytokines and growth factors that are involved
in a range of paracrine loops which lead to proliferation
of tumour cells and thus growth of the tumour
[6,18,26]. These cytokines and growth factors include:
platelet derived growth factor (PDGF), TNF-a and
transforming growth factor - beta (TGF-b), epidermal
growth factor (EGF) and IL-1 [6,14]. There are a num-
ber of studies showing that TAM infiltration correlates
with increased tumour cell proliferation and thus
increased growth of many tumours, including breast
cancer [27].
In vitro studies have shown that growth of malignant
lymphoma cells is regulated by macrophage-like stromal
cells: when highly malignant murine RAW117-H1 cells
were grown on a layer of J774A.1 (Balb/c macrophage
cell line), direct cell surface contact between the stromal
and lymphoma cells was needed for growth regulation
[28]. It has also been indicated that macrophage cell
surface components act synergistically with FIO 30 cells
(another murine lymphoma cell line) to support tumour
cell growth, only when cells were in close proximity
[29]. It would be of interest to determine if this cell-to-
cell contact is necessary in other cancers, especially
breast cancer. Evidence that TAMs support tumour
growth has also been reported in murine sarcoma cells
(MC1 cell line) which only grew in vitro when co-cul-
tures with peritoneal macrophages [30]. Moreover, the
inhibition of macrophage infiltration by transfecting IL-
10 into Chinese Hamster Ovary cells, suppressed subse-
quent tumour growth [31].
A review by Leek et al described how TAMs -that
secrete the majority of EGF in tumour stroma, preferen-
tially stimulated the breast tumour cells that express
EGF-receptors thereby creating a predominantly EGFR-
expressing tumour, which is correlated with poor survi-
val [14]. This process seems analogous to environmental
pressure and shows that, not only do tumours influence
the TAM phenotype, but TAMs can influence the over-
all tumour phenotype. Conversely there is also evidence
that TAMs can delay tumour growth by secretion of
factors such as nitric oxide and interferon gamma [32],
supporting the view that different areas of the tumour
can activate different TAM phenotypes [6].
The roles of TAMs in migration, invasion and intravasation
Several reports have proposed a chemotactic and para-
crine EGF/CSF-1 loop between macrophages and
tumour cells, which allows them to work synergistically
in an effort to co-migrate. Macrophages express CSF-1
receptors and produce EGF, whereas tumour cells
express EGF receptors and produce CSF-1. EGF stimu-
lates the migration of tumour cells and up-regulates the
production of CSF-1 which subsequently promotes
migration of TAMs. Thus the two cell types migrate
together in a co-dependent manner. This supports find-
ings by Lin et al who showed reduced infiltration of
macrophages into tumours in CSF-1 null mutant PyMT
mice and thus, reduced invasion by tumour cells [11].
Moreover, EGF and CSF-1 induce the formation of
invadopodia (in metastatic mammary adenocarcinoma
cells) and podosomes (in TAMs), respectively. Both are
involved in extra-cellular matrix (ECM) degradation and
remodelling, thus increasing invasion of both cell types
[33-37]. In in vivo models of breast cancer, this migra-
tory response is concurrent with invasion, intravasation
and metastasis [37].
Invasion of a tumour through the basement mem-
brane is the point at which it is classified as malignant
and marks the start of the metastatic cascade. TAMs, as
well as forming podosomes, are capable of secreting fac-
tors that break down areas of basement membrane, thus
allowing movement of tumour cells into the surround-
ing tissues. These include matrix metalloproteinases in
particular MMP-2, -3, -7 and -9 [37,38], enzymes
involved in ECM remodelling and thus, aid invasion.
MMP production by macrophages is stimulated by
TNF-a, a cytokine produced by tumour cells. In vitro
studies have shown that co-culture of breast cancer cells
and macrophages up-regulated MMP expression in
macrophages in a TNF-a dependent fashion, causing
enhanced invasiveness of the tumour cells [38]. These
findings were verified using a broad spectrum MMP
antagonist, which significantly reduced the invasion.
Similarly, addition of a TNF-a antibody reduced inva-
siveness and expression of MMP-2 and MMP-9 by
TAMs [38]. However, conflicting findings have been
reported on the necessity of cell surface contact dis-
cussed above [38].
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collagen fibrillogenesis and angiogenesis, where both cell
types move along collagen fibres attached to blood ves-
sels in a lockstep fashion.O n c et h e yr e a c ht h eb l o o d
vessels, macrophage aid tumour cells intravasation into
the circulation. In addition, invasion occurs at sites of
angiogenesis, and there is also evidence that macro-
phages promote collagen fibrillogenesis [39].
The role of TAMs in metastasis
In contrast to the role of macrophages in primary
tumours, little is known about the specific role of TAMs
in metastatic foci; the data suggests that macrophages
are also involved at the other end of the metastatic cas-
cade, aiding extravasation of tumour cells and the estab-
lishment of a proliferative niche. One study showed that
when carcinoma cells were injected into the portal vein,
mice with depleted peritoneal macrophages had reduced
tumour foci in the lungs, indicating that the macro-
phages were directly involved in seeding of the tumour
cells [40].
Studies of the effects of CSF-1 on tumour progression
and establishment of metastasis showed that mice defi-
cient in macrophage CSF-1 had delayed metastatic
spread of mammary tumours to the lungs. In contrast,
CSF-1 deficiency did not affect development or growth
of the primary tumour [11]. Tumour cells at primary
sites induce the expression of MMP-9 in macrophages
in the lungs which promotes angiogenesis, aiding
tumour cell establishment and growth at this metastatic
site [41]. Tumours in macrophage-depleted animals
grew to a large size but remained benign. This supports
the theory that macrophages are needed in the angio-
genic switch which is linked to metastatic potential [10].
The role of TAMs in immunosuppression
As discussed above M1 macrophages play important
roles in both arms of the immune system including pha-
gocytosis, antigen presentation and release of pro-
inflammatory cytokines and are therefore naturally
tumoricidal. In contrast, M2 macrophages show poor
immune-stimulatory and antigen presenting capabilities.
As would be expected, TAMs possess M2-like traits;
Tumour cells and the tumour microenvironment release
a variety of factors that facilitate this, including IL-4, IL-
6, IL-10, PGE2,T G F - b1 and CSF-1, expressed by
tumour cells, as well as IL-10, PGE2 and MMP-7
expressed by TAMs. IL-10, PGE2 and TGF-b have been
shown to suppress the proliferation and cytotoxicity of
T cells and NK cells by decreasing macrophage expres-
sion of IL-12. MMP-7 is shown to increase tumour cell
resistance to chemotherapeutic agents [42,43] and to
decrease tumour cell sensitivity to apoptosis [42,43],
both of which increase tumour survival.
Overall the evidence suggests that the down-regulation
of the normal immune-response to tumour cells by
TAMs allows tumours to grow unchecked as well as
aiding metastatic spread [6,15].
Correlation of TAMs to prognosis and survival
Due to TAMs extensive involvement in tumour progres-
sion, it is no surprise that TAM infiltration of the
tumour microenvironment has been correlated with
decreased patient survival, especially in breast cancer.
Histological analysis of 75 invasive breast cancers by Lee
et al showed that TAM infiltration was associated with
high tumour grade, tumour necrosis and large tumour
size [44]. Focal macrophage infiltration is reported to be
associated high vascular grade, increased necrosis and
decreased relapse-free and overall survival in invasive
breast cancer [19]. Moreover a meta-analysis found that,
in over 80% of cases of human malignancies, increased
TAM density was associated with poor prognosis [18].
This integral role that TAMs play in various processes
aiding tumour progression and metastasis, make them
an important and potential therapeutic target. One such
therapy could be the commonly used anti-resorptive
drugs nitrogen-containing bisphosphonates, which have
been shown to affect macrophages both in vitro and in
vivo as described in the following sections.
Bisphosphonates
Bisphosphonates are stable inorganic analogues of pyro-
phosphonate in which the central oxygen atom has been
replaced by a carbon atom (P-O-P vs P-C-P), see Figure
3. Bisphosphonates were originally used industrially in
fertiliser and as anticorrosive agents; however, after the
discovery of their ability to inhibit on osteoclast function
and hence bone resorption, they were refined for medi-
cal purposes. They currently play a fundamental part in
the treatment of many metabolic bone diseases includ-
ing: cancer-induced bone disease, Paget’s disease and
osteoporosis [45-47].
Figure 3 Structure of pyrophosphonate (top left), general
structure of a bisphosphonate (top right), structure of
clodronate (bottom left), alendronate (bottom middle) and
zoledronic acid (bottom right).
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The P-C-P structure of bisphosphonates forms the cen-
tral backbone to which two side chains, R1 and R2, are
covalently bonded. It is the presence or absence of
nitrogen on the R2 side chain that divides bisphospho-
nates into their two classes; nitrogen-containing bispho-
sphonates (N-BPs) and non-nitrogen containing
bisphosphonates (non N-BPs) [45-47] (see Figure 3).
Non-nitrogen containing bisphosphonates are metabo-
lically converted AppCl2p which inhibits the exchange
between ATP and ADP, impairing mitochondrial func-
tion and thereby inducing apoptosis [48-50].
Nitrogen containing bisphosphonates (also known as
amino-bisphosphonates or N-BPs) modify protein pre-
nylation by inhibiting farnesyldiphosphonate (FPP)
synthase, a key enzyme in the mevalonate pathway, pre-
sent in all eukaryotic cells [48-52], Figure 4. These
mechanisms will be discussed in greater detail below.
Mechanism of action of Nitrogen-containing
Bisphosphonates
N-BPs can further be classified into second generation
N-BPs (pamidronate and alendronate) and the more
potent third generation N-BPs (zoledronic acid and rise-
dronate). Third generation N-BPs include a heterocyclic
ring at R2, i.e. a nitrogen-containing ring. Both second
and third generation N-BPs are much more potent than
their non-nitrogen containing predecessors, due to their
increased actions on the mevalonate pathway
[46,47,52,53].
The mevalonate pathway is responsible for cholesterol
synthesis and post-transitional prenylation of a number
of molecules including small GTPases such as Ras (and
Ras-related proteins e.g. Rap1a). By inhibiting FPP
synthase, N-BPs reduce this protein prenylation, thereby
inducing apoptotic cell death. They can also, indirectly,
increase the synthesis of ApppI (an ATP analogue)
which is converted to AMP and IPP, the excess IPP
leads to apoptosis, similar to the mechanism of non N-
BP’s. Production of ApppI is a unique effect of N-BP’s.
Therefore N-BPs have two methods of inducing apopto-
sis; inhibition of FPP and excess production of IPP
[48-52].
Pharmacokinetics
Bisphosphonates are poorly absorbed in the gut due to
their negative charge hindering their transport across
the lipophilic cell membrane; they are therefore given
mainly intravenously [45,54]. BPs are not metabolised
and have very short plasma half lives, being distributed
q u i c k l yt ob o n eo re x c r e t e d unchanged by the kidneys
[45]. Due to their different potencies, there are marked
differences in recommended dosing concentrations as
well as minor differences in plasma and terminal half-
lives. A compilation of clinically relevant pharmacoki-
netic information is shown in Table 2.
As many studies included in this review use zoledro-
nic acid (ZOL), it is important to note the following
pharmacological information: The standard 4 mg clinical
dose of ZOL administered as an infusion every 3-4
weeks in the treatment of cancer-induced bone disease
has a plasma half life of 105 minutes and a peak plasma
concentration (CMax)o f1 - 2μM [55]. Peripheral tissues
will therefore receive only low doses of ZOL for short
time periods during clinical administration of this agent,
whereas many of the in vitro and in vivo studies that
Figure 4 Schematic diagram of the mevalonate pathway for
cholesterol synthesis. Nitrogen-containing bisphosphonates (N-
BPs) inhibit farnesyl diphosphate (FPP) synthase, preventing
synthesis of farnesyl diphosphate (FPP) and geranylgeranyl
diphosphate (GGPP) required for the prenylation of a number of key
proteins essential for cell survival. Inhibition of FPP synthase also
causes the accumulation of isopentenyl diphosphate (IPP), which is
incorporated into the cytotoxic metabolite ApppI (triphosphoric acid
1-adenosin-5’-yl ester 3-(3-methylbut-3-enyl) ester). Statins also act
through this pathway by inhibition of HMG-CoA reductase.
Table 2 Bisphosphonates relative anti-resorptive potency,
clinical dosage, and route of administration.
Bisphosphonate Potency Clinical Dose Route Ref.
Etidronate 1 Oral,
IV
[59]
Clodronate 10 1600 mg/day Oral [59,60]
Pamidronate 100 90 mg. 3-4 weeks IV [59,94]
Alendronate 1000 10 mg/kg oral. 1
mg/kg I.V)
Oral [59,62]
Ibandronate 1,000 -
10,000
6 mg 3-4 weeks IV [59]
Risedronate 1,000-
10,000
30 mg/d Oral [59]
Zoledronic acid 100,000 4 mg/2-3 weeks IV [3,59,95,96]
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extensive incubation periods.
Effects of Bisphosphonates on Osteoclasts
Because bisphosphonates home to bone very quickly due
to their high affinity for hydroxyapatite, they are present
in the skeleton for prolonged periods [56]. Osteoclasts
are the only cell type capable of resorbing bone and will
therefore be exposed to BPs bound to the bone matrix,
internalising the drug via endocytosis.
Once in the cell cytoplasm the bisphosphonate inhi-
bits protein prenylation, which is vital as the affected
signalling proteins are involved in many interactions
needed for cell survival, including: membrane ruffling,
integrin signalling and endosomal trafficking [56]. Inhi-
bition of prenylation in osteoclasts caused loss of the
ruffled border, disruption of cytoskeleton, altered intra-
cellular and extracellular protein signalling as well as
induction of apoptosis. Thus bisphosphonates inhibit
bone resorption by causing apoptotic osteoclast cell
death. This is the basis for their universal clinical use as
anti-resorptives f(57).
Anti-tumour activity of N-BPs - examples from breast
cancer
Bisphosphonates are an essential and standard part of
breast cancer treatment in the advanced setting, primar-
ily for their activity in bone. In addition, there is a
wealth of preclinical evidence showing N-BPs are cap-
able of affecting tumour cells directly, as well as have
anti-angiogenic effects [58].
Effect on tumour cells in bone
Breast cancer cells readily metastasise to bone where
they release osteolytic factors such as PTHrP,
prostaglandin-E and interleukins. These stimulate the
production of Receptor Activator of Nuclear Factor  B
ligand (RANKL) which binds to RANK receptors on
pre-osteoclasts causing increased osteoclastogenesis and
osteoclast activity, thus increasing bone resorption. As
bone is resorbed, growth factors such as TGF-b are
released which stimulate the proliferation of tumour
cells, and the process continues. This process, known as
the vicious cycle, is illustrated in Figure 5[59].
It is now well established that bisphosphonates reduce
cancer-induced bone disease by interfering with this
vicious cycle and osteoclast-mediated bone resorption.
This in turn reduces the risk of patients developing a
skeletal-related event (SRE) such as bone pain, patholo-
gical fractures and hypercalcaemia. On a molecular
level, bisphosphonates reduce the release of bone
derived growth factors, hence indirectly inhibiting
tumour cell proliferation.
Direct anti-tumour effects
Evidence from primarily in vitro but also some in vivo
studies have shown N-BPs can decrease tumour cell
proliferation, adhesion, migration and invasion, increase
apoptosis and decrease angiogenesis. These activities not
only lead to a reduction in skeletal tumour burden and
hinder the progression of bone metastasis, but may also
decrease tumour burden at the primary site.
Effects on tumour cell adhesion and invasion
The ability of N-BPs to inhibit tumour cell adhesion in
breast cancer was first reported by Van der Pluijm et al
who pre-treated bovine cortical bone slices with increas-
ing concentrations (1- 100 μM) of etidronate (ETI), clo-
dronate (CLO), pamidronate (PAM), olpadronate,
alendronate (ALN) and ibandronate (IBA) prior to
Figure 5 The Vicious Cycle of Cancer-induced bone disease.
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IBA, PAM, ALN and olpadronate (all N-BPs) all dose-
dependently inhibited adhesion and spreading of breast
cancer cells to bone, whereas ETI or CLO (non N-BPs)
had no effect. These findings are supported studies of
the effects of IBA, PAM and CLO treatment on subse-
quent adhesion of MDA-MB-231 and MCF-7 cells to
bone, showing that the drugs reduced adhesion with the
same order of potency as reported by Van der Pluijm et
al [60,61]. Bisphosphonate concentrations capable of
inhibiting adherence did not induce tumour cell apopto-
sis, and there was no inhibitory effect on fibroblasts
[60].
ZOL, CLO and IBA also showed dose-dependent inhi-
bition of MDA-MB-231 invasion, with the order of
potency of the remaining BPs was in concordance with
previous results (overall ZOL > IBA > PAM > CLO)
[60-62].
In vivo studies using murine models have reported
inhibition by ZOL on invasion and migration of breast
cancer cells. Female BALB/c mice injected with 4T1/luc
breast cancer were treated with intravenous ZOL (5
μM/mouse). Histological examination showed a signifi-
cant decrease in bone, lung and liver metastases in mice
that were repeatedly treated (4 times). There was no sig-
nificant increase in apoptosis of tumour cells in the
lungs or the liver, indicating that ZOL had a direct
effect at the primary tumour site; therefore it is possible
that intensive ZOL treatment can affect migration and
invasion of breast cancer cells in vivo [63].
Effects on apoptosis and proliferation
N-BPs can also induce significant tumour cell apoptosis
and inhibit cell proliferation in vitro. Investigating the
effects of N-BPs on viability and growth of breast cancer
cell lines, Fromigue et al showed that PAM, IBA and
ZOL (0.01-1000 μM) induced cell death mainly via
apoptosis in MCF-7 and via necrosis in T47D cells,
whereas no apoptosis was seen in MDA-MB-231 cells.
PAM, IBA and ZOL also decreased cell growth in a
dose- and time-dependent manner, in all cell lines (0.1-
1000 μM). ZOL was found to be the fastest acting N-
BP, inducing apoptosis within 2 hours (≥ 0.1 μM) in
MCF-7 cells and inhibiting cell growth within 3 hours.
This rapid effect may be clinically relevant as extra-ske-
letal exposure to BPs is very brief [64]. These findings
were supported by a number of subsequent studies;
Senaratne et al found that ZOL and PAM reduced cell
growth and viability by 50% in MDA-MB-231 and
MCF-7 cells at concentrations of 15 μMa n d2 0μM
(ZOL) and 40 μMa n d3 0μM( P A M ) .M o r e o v e rt h e s e
N-BPs induced cell apoptosis in all cell lines [65]. They
went on to show ZOL induced apoptosis via inhibition
of mevalonate pathway [66], which was supported by
Jagdev et al who also found that acute exposure to 100
μM of ZOL for just 2 hours caused significant induction
of tumour cell apoptosis, which is again, clinically
encouraging [64].
Effects of N-BPs on macrophages
Macrophages and osteoclasts are highly endocytic cells
that share the same lineage, so it would be logical that
bisphosphonates would affect macrophages. Using
macrophage like J774 cells, Thompson et al showed
that, in vitro, bisphosphonates are internalized into vesi-
cles by fluid-phase endocytosis; once inside the cell,
endosomal acidification caused the release of the
bisphosphonate into the cytosol. They concluded that
highly phagocytic cells such as macrophages have the
ability to internalise bisphosphonates which makes them
ideal targets for these drugs [67]. However, in vivo,t h i s
would be dependent on the pharmacokinetic properties
of the drugs, such as half-life in the circulation, as well
as the location of the target cells.
Due to the difficulty of studying osteoclasts in vitro,
early work on mechanism of action of bisphosphonates
was done on macrophage like J774 cells [50]. Bispho-
sphonates were shown to inhibit macrophage prolifera-
tion, migration, invasion, as well as cause apoptosis,
supporting that macrophages are potential N-BP targets
[49,51,53,56,68-70]. More recent studies have focussed
on how bisphosphonates affect “pro-tumoral factors”
produced by macrophages and the consequence of this
inhibition [21,71,72]. These effects will be covered in
more detail below.
Effects on apoptosis
While investigating the effects of bisphosphonates on
osteoclasts, Rogers et al found that pamidronate, alen-
dronate and ibandronate (100 μM/24 h) could inhibit
proliferation, reduce cell viability and cause apoptotic cell
death of macrophage-like J774 and RAW264 cells [68].
They subsequently discovered that apoptosis is due to
nitrogen-containing bisphosphonates (N-BPs) preventing
post-transitional protein prenylation by inhibiting a key
enzyme in the mevalonate pathway in these cells (see Fig-
ure 4 for exact mechanism). Studies of the potency of N-
BPs showed that the N-BP with the greatest antiresorp-
tive potency (heterocyclic-containing N-BP’s) reduced
J774 cell viability the most [50,73]. This provided the first
evidence that nitrogen containing bisphosphonates can
successfully modify macrophages in vitro.
Further studies explored how differences in R2 side
chain of N-BPs could affect their potency, and showed
that FPP synthase was inhibited by N-BPs in a dose-
dependent fashion, with the following order of potency:
ZOL > RIS > IBA > ALN > PAM [53]. These findings
are supported by data from J774A.1 macrophage-like
cells showing the same order of potency of the drugs in
relation to induction of apoptosis [49].
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ability to evoke the production of ApppI, which inhibits
the ability of mitochondrial ANT leading to excess IPP
accumulation and consequently cell apoptosis. The
order of potency of ApppI production in J774 macro-
phages is ZOL > RIS > IBA > ALN, whereas clodronate,
a simple BP does not induce ApppI production [51].
Taken together, ZOL is shown to be the most potent
inducer of apoptosis in macrophages in vitro,a s
expected due to its superior ability to evoke ApppI pro-
duction and inhibit FPP synthase.
Effects on proliferation
Bisphosphonates have also been shown to affect the pro-
liferation of macrophage precursors from bone marrow
cells and bone marrow-derived macrophages (BMDMs)
[69]. BMDMs obtained by flushing of long bones of 6-8
weeks old mice were treated with AHBuBP (nitrogen
containing but not heterocyclic BP) or AHPrBP (PAM)
for 96 hours. Compared with untreated BMDMs,
AHBuBP and PAM significantly inhibited M-CSF-
induced proliferation of bone marrow precursors at a
concentration of 0.25 μM, without evidence of cytotoxi-
city. Clodronate had less clear effects as there was an
overlap between cytotoxicity and inhibition of cell pro-
liferation, in agreement with reported effects of non-N-
BP’s on macrophage apoptosis [69]. Phagocytic mono-
cyte cells were shown to be more sensitive to BPs com-
pared to other cells in the haemopoietic series like
granulocytes.
Inhibition of pro-angiogenic factors: MMP-9
MMP-9 is a matrix metalloproteinase produced by
macrophages in response to stimulation by tumour-
d e r i v e df a c t o r s .I ti si n v o l v e di na n g i o g e n e s i sa n d
tumour cell invasion, key processes in the metastatic
cascade. Several studies have focussed on the effects of
bisphosphonates on macrophage production of MMP-9
and how this has modified tumour progression
[21,71,72].
Valleala et al investigated whether pamidronate or clo-
dronate altered the regulation of MMP-9 in activated
human monocyte/macrophages obtained from buffy
coat cells of healthy volunteers [71]. Macrophages were
pre-treated for 20-24 hours with CLO (3- 1000 μM) or
PAM (1- 300 μM) and then activated with LPS (lipopo-
lysaccharide) to increase the expression of inflammatory
cytokines including MMP-9 [71,74]. CLO significantly
inhibited MMP-9 expression in a dose-dependent fash-
ion at concentrations of 30-1000 μM, as did PAM at
concentrations of 100-300 μM. The authors suggest that
PAM had two effects on macrophages, firstly it
increased MMP mRNA stability, thereby increasing
MMP message levels, accounting for the increase in
MMP-9 expression at lower concentrations; secondly,
the higher concentrations inhibited protein prenylation
enough thus decreasing MMP-9 expression. This study
shows that bisphosphonates have an effect on macro-
phage MMP-9 expression in vitro.
MMP-9 inhibition by N-BPs may also have conse-
quences for myeloid-derived suppressor cell expansion
and macrophage infiltration in vivo. The MMP-9 -
VEGF loop not only supports angiogenesis and invasion
but “forces hyperactive haematopoiesis” which aids
tumour progression [21,38]. Moreover, VEGF causes
expansion of myeloid-derived suppressor cells (a popula-
tion characterised by immature macrophages, granulo-
cytes and dendritic cells) that are capable of suppressing
T-lymphocyte proliferation and T-cell activation; thus
they provide immunosuppression by the tumour
[75-77]. In addition to TAMs, myeloid-derived suppres-
sor cells have been described as one of the main antago-
nists of immunotherapies [76].
To investigate the effects of N-BPs on the relationship
between MMP-9, TAMs and MDSCs in vivo,B A L B -
neuT mice expressing activated mouse mammary
tumour virus (rat c-erbB-2/neu transgene) were treated
for 5 days per week with ZOL (0.1 mg/kg) or PAM (2
mg/kg,) [21]. Treatment was started at 3 different
points: 4 weeks (pre-hyperplastic), 7 weeks (hyperplastic)
and 12 weeks (detectable in-situ mammary carcinomas),
and continued until week 28. In mice treated from 4 or
7 weeks, PAM and ZOL delayed tumour onset,
decreased tumour volume and number of transformed
mammary glands. In mice receiving treatment from 12
weeks, PAM and ZOL decreased overall tumour volume.
ZOL decreased macrophage infiltration into the tumour
stroma associated with significantly decreased levels of
serum pro-MMP-9 and VEGF in all groups. This
decreased MDSC expansion in bone marrow and per-
ipheral blood, and consequently decreased immunosup-
pression. In support of these results, ZOL improved
immunotherapy outcome in FVB-BALB-neuT mice that
had received a plasmid DNA vaccine, decreasing overall
tumour volume and MDSC expansion.
Interestingly, Melani et al showed that ZOL appeared
to act preferentially on tumour-enhanced but not nor-
mal haematopoesis. The number of colonies in bone
marrow cells in BALB/c mice treated for 16 weeks with
ZOL and control mice were nearly identical. However,
decrease in MMP-9 and VEGF at the tumour site did
not impair angiogenesis, suggesting the presence of a
bypass route e.g. up-regulation of fibroblast growth fac-
tor, although this remains to be established [21]. ZOL
has also been shown to be effective at suppressing
macrophage MMP-9 expression in models of prostate
[78], and cervical carcinoma [72].
Importantly, these studies provide evidence that tar-
geting the production of MMP-9 within the tumour
microenvironment is a successful alternative to trying to
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city [21,71,72,78].
Inhibition of pro-angiogenic factors in clinical studies
VEGF is a major pro-angiogenic cytokine produced by
both tumour cells and TAMs and clinical studies have
focussed on how N-BP’s affect VEGF serum levels over
time. Santini et al investigated the effects a single infu-
sion of PAM could have on circulating VEGF levels
over 7 days. 25 patients with advanced solid tumour and
bone metastasis were infused with 90 mg of PAM and
their VEGF levels were measured 1, 2 and 7 days after
administration. The greatest significant decrease in
VEGF levels occurred 2 days after administration and
continuing up to 7 days post-administration; while these
results are interesting, this study did not include a can-
cer-free control cohort [79]. The same group has also
determined effects of 4 mg of ZOL in patients with
advanced solid cancer and bone metastasis and mea-
sured their VEGF (and PDGF) levels 1, 2, 7 and 21 days
after ZOL administration [80]. ZOL significantly
decreased circulating VEGF levels from 2 days after
administration and the effect was maintained until day
21. PDGF is another pro-angiogenic factor expressed by
TAMs, although it is less potent than VEGF. PDGF
levels fell significantly 1 and 2 days after ZOL adminis-
tration but that it returned to basal level by day 7
[79,80]. Similar findings are reported using the same
drug regime in advanced breast cancer patients; a signif-
icant reduction in circulating VEGF level at all time-
points (1, 2, 7 and 21 days after ZOL administration);
moreover the most significant decrease occurred 21
days after ZOL administration with over half the
patients showing a minimum of 25% reduction in circu-
lating VEGF [81].
These studies indicate that despite 4 mg of ZOL being
cleared from the circulation within hours of administra-
tion, the effects on VEGF serum levels are still signifi-
cant several weeks later. ZOL is slowly released from
bone into the circulation over the course of around 7
days, which could account for the continued reduction
of VEGF at this point. However, how ZOL is still modi-
fying VEGF levels at day 21 and which cell types that
are involved remains to be established [80-82]. Impor-
tantly, there was no correlation between ZOL induced
VEGF reduction and increased survival compared to
patients who did not experience a VEGF reduction in
this small study, demonstrating ZOL is not the complete
anti-cancer agent [81].
To determine whether more frequent dosing with
ZOL would cause a greater decrease in circulating
VEGF, effects of repeated low-dose therapy (metronomic
drug regime) on VEGF levels were investigated [82,83].
Patients with advanced solid cancer and bone metastases
received 1 mg of ZOL once a week for four weeks
followed 4 mg every 28 weeks (three times). VEGF levels
were measured at day 0 and again at 7, 14, 21, 28, 56
and 84 days. The results showed that these low doses
did indeed significantly decrease serum VEGF levels at
all time points.
The reports discussed above have shown that N-BP’s
significantly affect three pro-angiogenic factors like MMP-
9, VEGF and PDGF. However the cell type responsible is
unknown, and while these factors can all be expressed by
TAMs, they can also be expressed by tumour cells and
other stromal cells. However, these studies important as
they clearly demonstrate that treatment with ZOL alone
may affect tumour growth outside the skeleton.
Reversing M2 polarisation
Using a murine model of mammary carcinoma, Coscia
et al investigated the cellular effects of decreased VEGF
levels caused by clinically achievable doses of ZOL [83].
As discussed above, VEGF is one of the foremost factors
instigating the polarisation of macrophages from the M1
to the M2 phenotype. A few papers have focussed on
the effects of restoring M1 phenotype and the potential
anti-tumour results gained form this. Starting at 7
weeks of age, BALB-neuT mice were treated with 100
μM/kg of ZOL once a week for four weeks followed by
3 weeks rest; with the average mouse receiving 16 injec-
tions. ZOL treated mice showed significant increase in
tumour-free survival and overall survival, as well as sig-
nificant reduction in tumour growth rate and tumour
multiplicity, in comparison to control [77]. Histological
analysis showed significant decrease in the size of lung
metastases in ZOL treated mice compared to control,
and immunohistological staining showed that ZOL trea-
ted mice had impaired TAM recruitment and infiltration
into tumour stroma as well as clearly reduced neo-vas-
cularisation. Tumours from control mice had signifi-
cantly more intracytoplasmic VEGF staining (in TAMs
and tumour cells) compared to ZOL treated mice this
correlated to both a decrease in TAM density and in
serum VEGF levels. This is the first study showing that
ZOL reverses the polarity of peritoneal and tumour-
associated macrophages from M2 to M1. Macrophages
isolated from ZOL treated mice expressed iNOS, a pro-
tein considered the hallmark of M1 polarisation,
whereas control mice did not. This is a very important
finding, as M1 macrophages possess tumoricidal activity,
supporting that TAMS are a potential immune target of
ZOL therapy [8,83,84]. Moreover these data show that
BPs have a clear effect on tumour macrophages in vivo
following clinically relevant dosing.
Effect of bisphosphonate-induced macrophage depletion
on tumour growth in vivo
This review focuses mainly on the roles of macrophages
and the effect of bisphosphonates in the tumour
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TAMs have also been reported in other tumours.
Bisphosphonate-induced macrophage depletion has been
the focus of a number of studies using animal models of
metastatic lung cancer, metastatic liver cancer, mela-
noma and others (see Table 3 and 4). In these studies,
macrophages were mainly targeted using clodrolip; a
formulation of liposome encapsulated clodronate
(Cl2MDP-LIP) [85-88].
Macrophage depletion using Clodrolip alone
Hiraoka et al investigated the effects of clodrolip on
macrophage infiltration in BALB/c nude mice injected
with HARA-B lung cancer cell line, focusing on the
effect on bone and muscles metastasis [85]. Mice were
treated with either clodrolip (200 μL or 400 μLo n c e
every three days for 6 weeks) 10 mg/kg reveromycin A
daily for 6 weeks, or a PBS control. Clodrolip treated
mice had significantly reduced bone metastasis. Immu-
nohistochemical analysis of the tumours showed
decreased macrophage infiltration in clodrolip treated
mice in comparison to mice receiving PBS or
reveromycin A. The HARA-B lung cancer cells were not
affected by clodrolip in vitro, supporting that the effect
of clodrolip on metastatic spread was due to its actions
on macrophages rather than on the lung cancer cells
[85].
Clodrolip in combination with anti-cancer agents
The effects of clodrolip combined with MCP-1 inhibi-
tion have been investigated on tumour growth and
angiogenesis in a melanoma model. One day after the
first clodrolip treatment (50 μlo r2 0 0μl), athymic male
NIG(S)-Nu mice were injected with human melanoma
cell line IIB-MEL-J, IIB-MEL-J-MCP-1 (IIB-MEL-J cells
containing a MCP-1 expression vector) or a vehicle con-
trol. Treatment continued every 5-7 days, mice were
killed on day 4 or 11. Compared to control, clodrolip
caused a decrease in tumour volume greater than 70%
in IIB-MEL-J-MCP mice as well as increasing their sur-
vival, and this was associated with reduced tumour
angiogenesis. To identify which cell types that were tar-
geted, melanoma and endothelial cells (intrinsic for
angiogenesis) were treated in vitro with clodrolip, with
Table 3 Summary of in vitro studies reporting effects of bisphosphonate on macrophages
Cell Type Bisphosphonate Main Findings Reference
J774 cells
RAW 264 cells
PAM, ALN, IBA, 100
μM
24 hours
Inhibited macrophage proliferation.
Reduced cell viability. Increased cell death.
Rogers et al
[68]
J774 cells ALN, 25 μM or 100
μM
IBA 5 μM, 7.5 μMo r
10 μM
24 hours
Dose dependent increase in accumulation of unprenylated Rap1A. Firth et al
[97]
RAW 264 cells ALN 10 μM; 5, 7, 9 or
16 hours
ALN 100 μM; 1, 3, 5,
7, 9, 16 hours.
Dose and time dependent increase in accumulation of
unprenylated Rap1A. Detectable after 16 hours incubation with 10
μM or 5 hours incubation with 100 μM
Monkkonen
et al [98]
J774 A.1 cells PAM, ZOL, ALN, RIS
1-100 μM for 72
hours.
All BPs induced significant apoptosis
ZOL > RIS > ALN > PAM.
Moreau
et al [49]
Macrophage precursor from bone
marrow cells and bone marrow derived
macrophages
PAM
2.5 × 10
-7M (=0.25
μM), 96 hours
Significant inhibition M-CSF induced proliferation of bone marrow
precursors
Cecchini
et al [69]
Activated human monocyte/
macrophage
PAM
100-300 μM
24 hour pre-
treatment Then
activated with LPS.
Dose-dependent inhibition of MMP-9 expression
Lower doses PAM increases expression.
Valleala et al
[71]
Human macrophage-like cell line U937 Clodrolip
20-200 μM
2 days
Decreased cell survival Hiraoka et al
[85]
Murine Macrophages Clodrolip
9 μg per well
29 hours
Decreased cell viability Gazzangia
et al [86]
Murine peritoneal macrophages Clodrolip
1 mg/ml
6 hours.
Dose-dependent increase in apoptosis. Zeisberger
et al [87]
Bone marrow cells from naive mice
cultured with M-CSF or tumour
supernatant.
Zoledronic acid
0.03, 0.15, 0.3 μM
6 days
Dose-dependent inhibition in differentiation of myeloid cells to
macrophages.
Decreased in M2 phenotype compared to control.
Veltman
et al [89]
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the findings of Hiraoka et al and confirms a direct rela-
tionship between depletion of TAMs and reduction in
angiogenesis, tumour growth and increased survival
[85,86].
TAM depletion has also been combined with an anti-
angiogenic therapy using VEGF neutralising antibody.
Female Sv129 mice injected with F9 teratocarcinoma
cells and CD-1 nude mice injected with A673 rhabdo-
myoscarcoma cells were treated with either 1 mg20 g
-1
clodrolip (initial dose 2 mg20 g
-1), clodronate dissolved
in phosphate buffer (67 mM) or anti VEGF Abs 0.5
mg20 g
-1 i.v. or clodrolip and anti VEGF Abs in combi-
nation. F9 mice treated with clodrolip had an 82%
reduction in tumour volume, while those treated in
combination had 92% reduction. Similar results were
obtained in A673 mice. Immunohistochemical staining
of tumours from A673 animals showed a significant
reduction in blood vessel density (CD31+) (89% with
clodrolip alone and 85% in combination therapy), this
reduction was significant up to 9 days after the end of
therapy. Clodrolip-treated animals also exhibited a 93%
depletion of TAMs which was not enhanced by
combination treatment. As shown for other tumour cell
types clodrolip had no effect on F9 or A673 in vitro,
supporting that the effects on tumour volume were due
to TAM depletion [87].
The multi-targeted kinase inhibitor sorafenib has
been combined with clodrolip or ZOL in models of
metastatic liver cancer. The human hepatocellular can-
cer cell lines LM3R and SMMC7721 were orthotopi-
cally implanted into the liver of BALB/c nu/nu mice,
and animals were treated with sorafenib (30 mg/kg
daily), clodrolip (100 μg/kg three times per week), ZOL
(100 μg/kg three times per week), or sorafenib com-
bined with clodrolip or ZOL. Mice treated with sorafe-
nib alone showed increased tumour macrophage
infiltration and peripheral blood monocytes compared
to control, however, mice receiving ZOL or clodrolip
alone showed no significantly suppressed infiltration
and decreased peripheral blood monocytes. Mice
receiving ZOL or clodrolip alone showed no significant
difference in either compared to control. Overall, com-
bination treatment caused significantly decreased
tumour growth, decreased angiogenesis, and decreased
lung metastasis [88].
Table 4 Summary of in vivo studies investigating bisphosphonate effects on macrophages
Model Bisphosphonate Main Findings Reference
BALB-neut mice with mammary
tumour virus (rat c-erb-2-neu/
transgene)
ZOL 0.1 mg/kg or
PAM 2 mg/kg
5 days a week.
Zol decreased macrophage infiltration into tumour
stroma associated with decreased levels of pro-
MMP-9 and VEGF
Melani C
et al [21]
Mammary carcinoma cells implanted in
BALB-neutT mice
ZOL
100 μM/kg Once a week for 4 weeks,
followed by 3 weeks rest, cycle
continued.
Impaired TAM recruitment and infiltration into
tumour and reduced neo-vascularisation reversal of
TAM polarity from pro-tumoural M2 to tumoricidal
M1
Coscia et
al [83]
HARA-B lung cancer cells implanted in
BALB/c nude mice
Clodrolip
200 μL or 400 μL Every 3 days for 6
weeks (s.c.).
Reduced TAM infiltration correlated to reduced
metastatic spread
Hiraoka et
al [85]
Human melanoma cell line IIB-MEL-J
with or without MCP-1 expression
vector. Athymic male NIC-(S)-Nu mice
Clodrolip 50 μl or 200 μl( 6m g
clodronate per 1 ml ) From day before
cell injection and every 5 to 7 days
thereafter.
Reduced TAMs infiltration correlated to decreased
tumour volume and angiogenesis and increased
survival
Gazzangia
et al [86]
F9 teratocarcinoma cells implanted in
SV129 female mice
Clodrolip, 1 mg/20 g every 4 days. Reduced TAM infiltration.
82% reduction in tumour volume
Zeisberger
et al [87]
A673 rhabdomyosarcoma cells into
CD-1 nude mice
Clodrolip, 1 mg/20 g every 4 days. 93% reduction in TAM
89% reduction in blood vessel density
Zeisberger
et al [87]
Metastatic liver cancer Mouse model
LM3R or SMMC7721 human
hepatocellular cell lines in BALB/c nu/
nu mice
Clodrolip 100 μg/kg
3 times a week or, ZOL 100 μg/kg 3
times a week and or 30 mg/kg sorafenib.
Reduced TAM infiltration with combination therapy.
Correlated with decreased tumour growth,
angiogenesis and lung metastasis. ZOL had greater
effect than clodrolip
Zhang et
al [88]
Cervical carcinoma K14-HPV16
transgenic mice
ZOL
100 μg
Every day for 3 months.
Decreased MMP-9 expression by TAMs Giraudo et
al [72]
Peritoneal macrophage obtained from
CBA-J mice injected with AC29
mesothelioma cells
Clodronate 200 μl twice over 10 days. Depleted peritoneal macrophages.
Decreased tumour growth
Veltman et
al [89]
CBA-J mice injected with AC29
mesothelioma cells
ZOL
100 μg/kg s.c.
Every day for 25 days.
Increased myeloid precursors.
Decreased TAMs No significant increase in survival
or decrease in tumour burden
Veltman et
al [89]
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The effects of ZOL differentiation of macrophages from
myeloid cells to TAMs has been studies in CBA-j mice
injected with AC29 mesothelioma cells [89]. Mice
receiving 2 doses of intraperitoneal clodrolip (day 5 and
10) had significantly decreased numbers of macrophages
in the peritoneal cavity. Tumour growth was reduced in
all treated animals on day 12, with 60% of the mice fail-
ing to develop tumours, demonstrating that macro-
phages play a significant role in tumour development in
this model. In the same study, mice were treated daily
with 100 μg/kg ZOL for 25 days following implantation
of AC29 cells. ZOL induced reversal of TAM polarisa-
tion from the M2 e to the M1 phenotype, and higher
numbers of myeloid precursors and lower numbers of
TAMs were detected in ZOL treated mice compared to
control. However, tumour burden and survival were
unaffected by ZOL. The authors hypothesised that ZOL
treatment may result in up-regulation of a sub-popula-
tion of immature myeloid cells with immunosuppressive
properties [89]. Despite using a very intensive ZOL
schedule (equivalent to the 4 mg clinical dose given
daily for several weeks), this study failed to demonstrate
a significant anti-tumour effect.
Optimising ZOL delivery using nanothechnology
Recent studies have aimed at optimising the delivery of
ZOL using nanotechnology, in an attempt to overcome
the limitations of its pharmacokinetic properties and
thus extend the exposure time of extra-skeletal tumours
to these agents [90-92]. Two delivery systems have been
developed where ZOL is either encapsulated in stealth
liposomes or in PEGlyated nanoparticles. Administration
of stealth liposomes (LIPO-ZOL) was well tolerated and
found to significantly reduce tumour growth and
increase survival in mouse models of human prostate
cancer and multiple myeloma [93]. The second
approach involved encapsulation of ZOL in PEGylated
particles of calcium phosphate (PLCaPZ NP), and two
forms, pre-PLCaZ NP and post-PLCaZ NP, have been
tested both in vitro and in vivo [92]. First the effects of
PLCaPZ NPs on growth in vitro was determined in a
number of cancer cell lines including prostate, breast,
lung, pancreas and multiple myeloma. Pre-PLCaPZ NPs
had highest anti-proliferative effect, and was subse-
quently tested in an in vivo model of prostate cancer.
CD-1 nude mice were injected with human prostate
cancer cells (PC-3) and divided into groups receiving
either control, blank NPs, free ZOL or pre-PLCaPZ NPs
(0.25 mg/ml) three times per week for three weeks. Ani-
mals treated with PLCaPZ NP showed 45% tumour
weight inhibition and a tumour growth delay of 10 days,
and this was significantly greater than in mice treated
with free ZOL [92]. In a recent study comparing LIPO-
ZOL to PLCaPZ NPs and free ZOL, CD-1 male nude
mice were injected with human prostate cancer cells
and placed in one of six treatment groups: untreated,
empty NPs, empty liposomes, free ZOL, LIPO-ZOL (108
μg/ml) and PLCaNPs (66 μg/ml) and treated three times
a week for three consecutive weeks [91]. PLCaNZ NPs
delayed tumour grown by 12 days, significantly longer
than LIPO-ZOL (7 days) and free ZOL (3 days). More-
over, PLCaPZ NP caused 65% necrotic index and also
induced strong anti-angiogenic effects, both significantly
greater than compared to LIPO-ZOL [91]. Most inter-
esting in regard to this review was the immunohisto-
chemical staining showing tumours of LIPO-ZOL and
PLCaPZ NP treated animals had 28% and 18% of
TAMs, respectively. This was significantly less than the
numbers found in controls or animals receiving free
ZOL. Encouragingly, ZOL only affected TAMs and the
presence of macrophages in normal tissues was not
altered [91].The combination of anti-tumour and anti
tumour-associated macrophage effects of PLCaNZ NPs
may be due to this delivery method resulting in a longer
elevation of plasma ZOL. Further studies with other
tumour types in vivo, especially breast cancer models,
would be of interest.
Conclusions
Bisphosphonates are routinely used in the treatment of
cancer-induced bone disease, and there is a growing
body of evidence both in vitro and in vivo supporting
their potential anti-tumour activity, mainly from studies
focussing on effects of tumour cells. However, as sum-
marised in this review, bisphosphonates may also affect
tumour growth by modifying cells of the tumour micro-
environment. Bisphosphonates induce macrophage
apoptosis in vitro and to inhibit the release of pro-
angiogenic factors, and there is evidence showing that
bisphosphonates can affect tumour macrophages in vivo
by reversing their polarity to tumoricidal phenotype.
Whereas data from model systems suggest that effects
on macrophages in tumour microenvironment could
contribute to the bisphosphonate anti-tumour effects,
whether macrophages could be a target of these agents
following clinical dosing remains to be determines. To
firmly establish the potential for targeting of tumour
macrophages with bisphosphonates requires in vivo stu-
dies using clinically relevant dosing regimens as well as
analysis of TAMs in tumour material from neoadjuvant
studies of patients receiving bisphosphonate treatment.
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